Tempus AI, Inc. (TEM) Spending and interest coverage
- R&D / revenue · 12 months: Value 13.71%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 13.00%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 13.71% | Research and development expense / revenue. Period ending 2026-06-30. $196.31M ÷ $1.43B × 100 ≈ 13.71% |
| Stock-based compensation / revenue · 12 months | 13.00% | Share-based compensation / revenue. Period ending 2026-06-30. $186.15M ÷ $1.43B × 100 ≈ 13.00% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 196.31M USD | Research and Development Expense |
| Revenue | 1.43B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 186.15M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -283.03M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $196.31M | $1.43B | $186.15M | $-283.03M | (m) | 13.71% | 13.00% | (m) | (m) |
| 2026-03-31 | $185.29M | $1.36B | $154.48M | $-268.89M | (m) | 13.58% | 11.32% | (m) | (m) |
| 2025-12-31 | $172.92M | $1.27B | $124.75M | $-252.87M | (m) | 13.60% | 9.81% | (m) | (m) |
| 2025-09-30 | $152.06M | $1.11B | $104.19M | $-242.16M | (m) | 13.76% | 9.43% | (m) | (m) |
| 2025-06-30 | $134.45M | $951.98M | $91.25M | $-234.78M | (m) | 14.12% | 9.59% | (m) | (m) |
| 2025-03-31 | $160.86M | $803.32M | $557.11M | $-706.50M | (m) | 20.02% | 69.35% | (m) | (m) |
| 2024-12-31 | $149.32M | $693.40M | $534.14M | $-691.08M | (m) | 21.54% | 77.03% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $90.34M | $531.82M | $0.00 | $-196.08M | (m) | 16.99% | 0.00% | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $83.16M | $320.67M | $0.00 | $-265.44M | (m) | 25.93% | 0.00% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.